Latest News for: pdac

Edit

Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (ASEBIO - Asociación Española de Bioempresas)

Public Technologies 14 Jan 2026
) Partners EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the ...
Edit

UPCOMING: PDAC 2026 Convention Toronto, ON March 1–4, 2026 (Volt Carbon Technologies Inc)

Public Technologies 09 Jan 2026
). PDAC 2026. The World's Premier Mineral Exploration & Mining Convention will take place from March 1-4 in Toronto, Canada ... Attachments Original document Permalink. Disclaimer. Volt Carbon Technologies Inc ... (noodl. 128808556) .
Edit

Phanes Therapeutics Announces Positive Phase 2 Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline (1L) Treatment of Metastatic PDAC at ASCO GI 2026

PR Newswire 09 Jan 2026
SAN DIEGO, Jan ... Phanes Therapeutics, Inc ... The data was presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) 2026; Abstract #709 ... multi-center study with spevatamig ... Of note ... No CRS was observed ... CONTACT ... 21% ... .
Edit

Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (Form 8-K) (Theriva Biologics Inc)

Public Technologies 29 Dec 2025
Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC).
Edit

Phanes Therapeutics to Present Phase 1/2 Study Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline (1L) Treatment of Metastatic PDAC at ASCO GI 2026

PR Newswire 09 Dec 2025
SAN DIEGO, Dec. 9, 2025 /PRNewswire/ -- Phanes Therapeutics, Inc ... This marks the first public release of Phanes' clinical trial data from their ongoing U.S. multi-center study with spevatamig. Details of the presentation are below.. Title ... Abstract #. 709 ... .
Edit

2025 PDAC (Volt Carbon Technologies Inc)

Public Technologies 02 Dec 2025
). Suite 117 - Arcuri Business Centre 70 Country Hills Landing NW Calgary, AB T3K 2L2. P. (519-763-1197). Email. info@voltcarbontech.com Web. https.//www.voltcarbontech.com ... November 19, 2025, Calgary, AB, Canada - Volt Carbon Technologies Inc ... VCT) (OTCQB.
Edit

TAP Sleep Care Secures Full Medicare Portfolio Coverage: Nylon flexTAP® Receives PDAC Approval

Enid News & Eagle 01 Dec 2025
... Data Analysis, and Coding (PDAC) approval for .
Edit

MHRA Approves BetaGlue Therapeutics’ Clinical Trial Application for YntraDose™ in unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)

Pharmiweb 13 Nov 2025
LA-PDAC remains a significant health concern and an unmet medical need. The incidence of LA-PDAC has increased by 1.0% per year since the late 1990s, and it is projected to become the second-leading cause of cancer-related mortality by 2030.
Edit

Blue Lagoon Resources Inc. (VAN:BLLG) Wins PDAC 2026 Sustainability Award - Ellis Martin Report with Rana Vig (Blue Lagoon Resources Inc)

Public Technologies 06 Nov 2025
). The text version of this document is not available ... Disclaimer ... (noodl. 127579577) .
Edit

Blue Lagoon Resources Selected for PDAC's 2026 Sustainability Award (Blue Lagoon Resources Inc)

Public Technologies 05 Nov 2025
). The text version of this document is not available ... Disclaimer ... (noodl. 127532482) .
Edit

PDAC announces 2026 Awards recipients

Resource World 05 Nov 2025
The Prospectors & Developers Association of Canada (PDAC) is pleased to announce the recipients of the 2026 PDAC Awards, celebrating the people and partnerships driving discovery, development, and sustainable growth in the mineral industry.
  • 1

Article Search

tools
×
×
×
×